| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 915 | 2021 |
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 879 | 2019 |
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ... The lancet oncology 16 (2), 169-176, 2015 | 485 | 2015 |
| TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy CW Eskelund, C Dahl, JW Hansen, M Westman, A Kolstad, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 130 (17), 1903-1910, 2017 | 375 | 2017 |
| Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open … O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ... The Lancet Oncology 21 (9), 1188-1200, 2020 | 310 | 2020 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 264 | 2020 |
| B-cell receptor signaling as a driver of lymphoma development and evolution CU Niemann, A Wiestner Seminars in cancer biology 23 (6), 410-421, 2013 | 261 | 2013 |
| Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA … AC Rawstron, KA Kreuzer, A Soosapilla, M Spacek, O Stehlikova, ... Cytometry Part B: Clinical Cytometry 94 (1), 121-128, 2018 | 230 | 2018 |
| ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, ... Leukemia 32 (5), 1070-1080, 2018 | 219 | 2018 |
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study SEM Herman, CU Niemann, M Farooqui, J Jones, RZ Mustafa, A Lipsky, ... Leukemia 28 (11), 2188-2196, 2014 | 216 | 2014 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 215 | 2018 |
| Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study CU Niemann, SEM Herman, I Maric, J Gomez-Rodriguez, A Biancotto, ... Clinical Cancer Research 22 (7), 1572-1582, 2016 | 210 | 2016 |
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib AH Lipsky, MZH Farooqui, X Tian, S Martyr, AM Cullinane, K Nghiem, ... Haematologica 100 (12), 1571, 2015 | 179 | 2015 |
| The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia SEM Herman, A Montraveta, CU Niemann, H Mora-Jensen, M Gulrajani, ... Clinical Cancer Research 23 (11), 2831-2841, 2017 | 161 | 2017 |
| Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy M Helleberg, CU Niemann, KS Moestrup, O Kirk, AM Lebech, C Lane, ... The Journal of infectious diseases 222 (7), 1103-1107, 2020 | 151 | 2020 |
| Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial M Jerkeman, CW Eskelund, M Hutchings, R Räty, KF Wader, A Laurell, ... The Lancet Haematology 5 (3), e109-e116, 2018 | 142 | 2018 |
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood TM Herndon, SS Chen, NS Saba, J Valdez, C Emson, M Gatmaitan, ... Leukemia 31 (6), 1340-1347, 2017 | 137 | 2017 |
| Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities AP Kater, C Owen, C Moreno, G Follows, T Munir, MD Levin, O Benjamini, ... NEJM evidence 1 (7), EVIDoa2200006, 2022 | 126 | 2022 |
| Neutrophil elastase depends on serglycin proteoglycan for localization in granules CU Niemann, M Åbrink, G Pejler, RL Fischer, EI Christensen, SD Knight, ... Blood 109 (10), 4478-4486, 2007 | 122 | 2007 |
| First-line venetoclax combinations in chronic lymphocytic leukemia B Eichhorst, CU Niemann, AP Kater, M Fürstenau, J Von Tresckow, ... New England Journal of Medicine 388 (19), 1739-1754, 2023 | 113 | 2023 |
mark-david levin在 asz.nl 的电子邮件经过验证
